The companies developing new weight-loss medicines have a problem: the balance of power has shifted, and patients are bailing ...

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

By Christy Santhosh March 19 (Reuters) - Eli Lilly's next-generation obesity drug showed a significant reduction in blood ...

The GLP-1 PR has been a little too good. Everyone knows the drugs lead to rapid weight loss — including participants in ...

Imcivree’s approval in a type of obesity driven by brain injury could unlock an opportunity Wall Street analysts believe to ...

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

The U. Food and Drug Administration expanded the use of Rhythm Pharmaceuticals’ therapy for a ‌rare form of obesity caused by ...

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

Rhythm Pharmaceuticals is switching up the tempo for its melanocortin-4 receptor (MC4R) agonist Imcivree. | The new FDA nod makes Rhythm Pharma's Imcivree the first approved drug for acquired ...

Chugai Pharmaceutical Co. fell 7.3%, the largest intraday decline since August 2025, after the company said it had ended the ...

The FDA has approved a higher 7.2 mg dose of Novo Nordisk’s Wegovy (Wegovy HD) for chronic weight management in adults with ...

Medical researchers at the University of Pittsburgh published findings that could lead to the next generation of weight-loss medication. Dr. Isin Cakir and his team published a paper in the journal ...